Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)

被引：0
|
作者：
Zhang, H. [1 ]
Liu, L. [1 ]
Zhu, X. [1 ]
Gao, Y. [1 ]
Tong, Z. [1 ]
Fu, Q. [1 ]
Bao, X. [1 ]
Dai, X. [1 ]
Zhao, P. [1 ]
Fang, W. [1 ]
Zheng, Y. [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Oncol Dept, Sch Med, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
41P
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [41] Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC)
    Carneiro, B. A.
    Bahary, N.
    Lembersky, B.
    Fakih, M.
    Krishnamurthi, S. S.
    Lancaster, S.
    Pinkerton, R.
    Crandall, T.
    Potter, D.
    Ramanathan, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).
    Peeters, Marc
    Oliner, Kelly Smith
    Price, Timothy Jay
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew
    Wilson, Gregory
    Ciuleanu, Tudor E.
    Roman, Laslo
    Van Cutsem, Eric
    Yu, Hua
    Jung, Andre Scott
    Sidhu, Roger
    Patterson, Scott D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Johnson, Benny
    Haymaker, Cara L.
    Parra, Edwin R.
    Soto, Luisa Maren Solis
    Wang, Xuemei
    Thomas, Jane, V
    Dasari, Arvind
    Morris, Van K.
    Raghav, Kanwal
    Vilar, Eduardo
    Kee, Bryan K.
    Eng, Cathy
    Parseghian, Christine M.
    Wolff, Robert A.
    Lee, Younghee
    Lorenzini, Daniele
    Laberiano-Fernandez, Caddie
    Verma, Anuj
    Lang, Wenhua
    Wistuba, Ignacio I.
    Futreal, Andrew
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
  • [44] Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
    Lee, Choong-kun
    Jung, Minkyu
    Park, Sejung
    Kwon, Woo Sun
    Kim, Kyoo Hyun
    Hong, Moonki
    Kim, Hyunwook
    Kim, Hyo Song
    Chung, Hyun Cheol Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 374 - 374
  • [45] Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
    Xu, Yun
    Wu, Yuchen
    Dai, Yuedi
    Ji, Xiaopin
    Cui, Zhe
    Zhu, Xiaodong
    Xu, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 151 - 151
  • [46] Preliminary results of bevacizumab plus raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): A multicenter phase II trial
    Li, S.
    Zhu, L.
    Zhu, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S723 - S723
  • [47] Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial
    Taieb, J.
    Bouche, O.
    Andre, T.
    Barbier, E.
    Laurent-Puig, P.
    Bez, J.
    Toullec, C.
    Borg, C.
    Randrian, V.
    Evesque, L.
    Corbinais, S.
    Buecher, B.
    Perrier, H.
    Di Fiore, F.
    Gallois, C.
    Lepage, C.
    El Hajbi, F.
    Tougeron, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1391
  • [48] Toripalimab with Fruquintinib as the third-line treatment for refractory advanced metastatic colorectal cancer: Results of a single-arm, single-center, prospective, phase II clinical study.
    Ma, Shoucheng
    Chen, Rui
    Hou, Xiaoming
    Duan, Lin
    Li, Chunmei
    Yang, Tianning
    Ling, Xiaoling
    Zhao, Da
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15573 - E15573
  • [49] Exploratory biomarker analyses in phase 1 study of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Ye, Jian
    Wang, Chongkai
    Egelston, Colt
    Guo, Weihua
    Lee, Peter P.
    Fakih, Marwan
    CANCER RESEARCH, 2023, 83 (07)
  • [50] Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC)
    Wong, Vanessa
    Hong, Wei
    Ananda, Sumitra
    Dunn, Catherine
    Wong, Rachel
    To, Yat Hang
    Burge, Matthew E.
    Nott, Louise M.
    Tie, Jeanne
    Shapiro, Jeremy David
    Jennens, Ross
    Khattak, Muhammad Adnan
    Roohullah, Aflah
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345